# Allurion Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/allurion-technologies

- Industry: Medical Devices & Equipment
- Headquarters: Boston, US
- Website: www.allurion.com
- Total disclosed funding: $61M
- Latest round: Series D (Jul 1, 2021)
- Investors on record: 5

## About

Based in Massachusetts, US, and established in 2009, Allurion Technologies, Inc., a.k.a Allurion, f.k.a SGL Medical, Inc. operates as a developer of a novel weight loss program using gastric balloons. The company was co-founded by its CEO, Shantanu Gaur, and Samuel Levy, and in 2021, Allurion received an investment from Segulah Medical Acceleration (SMA). In 2022, the firm closed its Series D funding from Novalis LifeSciences and Romulus Capital. As of 2023, the company’s program is used in more than 60 countries worldwide.

The firm offers a weight loss program called Elipse Program that leverages its flagship product, Elipse balloon, an intra-gastric pill balloon designed to be swallowed and removed without the need for any invasive techniques such as surgery, endoscopy, anesthesia, etc. Through Allurion’s proprietary program, individuals or patients with obesity can lose approximately 10-15% of their body weight within 16 weeks. Additionally, the company offers Allurion-connected scales, health tracker devices, and a mobile app to support clients throughout their weight-loss journey.

## Funding rounds

- Series D, Jul 1, 2021 — Segulah Medical Acceleration
- Series D, Jan 7, 2020, $34M — Romulus Capital, IDO Investments, Novalis LifeSciences
- Series C, Jul 11, 2017, $27M — Romulus Capital, Cogepa, IDO Investments

## Investors

- Romulus Capital — Series C, Series D
- Cogepa — Series C
- IDO Investments (https://capitalatlas.ai/funds/ido-investments) — Series C, Series D
- Novalis LifeSciences (https://capitalatlas.ai/funds/novalis-lifesciences) — Series D
- Segulah Medical Acceleration (https://capitalatlas.ai/funds/segulah-medical-acceleration) — Series D